Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hbpd.2025.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of intraoperative autotransfusion use during liver transplantation for hepatocellular carcinoma on recurrence-free survival: comparative study with propensity score matching.
BJS Open
September 2025
Digestive Surgery and Transplantation Department, Toulouse University Hospital Centre, Toulouse, France.
Background: Intraoperative autotransfusion remains underutilized in high-risk haemorrhagic oncological procedures, particularly in liver transplantation for hepatocellular carcinoma. This is because of the theoretical risk of tumour cell reinfusion and dissemination, potentially leading to reduced recurrence-free survival. The aim of this study was to evaluate the impact of intraoperative autotransfusion on recurrence-free survival during liver transplantation for hepatocellular carcinoma.
View Article and Find Full Text PDFExtracorporeal Photopheresis Stimulates Tissue Repair after Transplantation.
Transplant Direct
September 2025
Laboratory for Transplantation Research, Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Extracorporeal photopheresis (ECP) is a safe and effective therapy with long-established indications in treating T cell-mediated immune diseases, including steroid refractory graft-versus-host disease and chronic rejection after heart or lung transplantation. The ECP procedure involves collecting autologous peripheral blood leucocytes that are driven into apoptosis before being reinfused intravenously. ECP acts primarily through in situ exposure of recipient dendritic cells and macrophages to apoptotic cells, which then suppress inflammation, promote specific regulatory T-cell responses, and retard fibrosis.
View Article and Find Full Text PDFTransplantation of Autologous Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Decompensated Liver Cirrhosis: A Real-World Evidence Study in a Population-Based Cohort.
Gut Liver
September 2025
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Background/aims: Despite medical advances in recent decades, the mortality rate of advanced liver cirrhosis remains high. Although liver transplantation remains the most effective treatment, candidate selection is limited by donor availability and alcohol abstinence requirements. Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has shown promise for the treatment of advanced cirrhosis.
View Article and Find Full Text PDFMyth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience.
Transpl Immunol
September 2025
Department of Hematology, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Turkey.
Acute graft-versus-host disease (aGvHD) is a rare but clinically significant complication of autologous hematopoietic cell transplantation. The aim of this retrospective multicenter study was to evaluate the clinical features, outcomes and risk factors associated with autologous graft-versus-host disease (auto-GvHD) in 19 patients. The cohort included 12 multiple myeloma and 7 lymphoma patients with a median age of 58 years.
View Article and Find Full Text PDFManagement of pediatric portal vein cavernous transformation: a seven-case single-center study.
Front Pediatr
August 2025
First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Background: Cavernous transformation of the portal vein (CTPV) is one of the significant pathogenic factors of prehepatic portal hypertension in children. The Rex shunt, by reconstructing an intrahepatic portal venous pathway, not only effectively reduces portal pressure and restores physiological hepatic blood flow, but also promotes normal growth and development, making it the treatment of choice for CTPV. In contrast, traditional non-selective shunting procedures primarily alleviate symptoms of portal hypertension without restoring hepatic perfusion, thereby compromising growth potential.
View Article and Find Full Text PDF